New shot tested for Tough-to-Treat eczema
Disease control
Not yet recruiting
This study is testing a new injectable antibody called SM17 for adults with moderate to severe atopic dermatitis (eczema) that doesn't respond well to standard creams. About 200 participants will receive either SM17 or a placebo shot to see if it safely reduces the severity of th…
Phase: PHASE2 • Sponsor: SinoMab BioScience Ltd • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC